EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...
Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...
EU regulators have issued a positive opinion for the extension of the market authorization for subcutaneous formulation of ...
Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received a positive opinion from the ...
Zacks.com on MSN1d
CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's ImfinziThe CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in ...
DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...
Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...
The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...
Department of Biology, University of Naples Federico II, Naples, Italy Telethon Institute of Genetics and Medicine, Naples, Italy U.O.C. Genetica Medica, IRCCS Istituto Giannina Gaslini, Genova, Italy ...
Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback